Other
Yi Fang
Total Trials
2
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 1
1(50.0%)
Phase 4
1(50.0%)
2Total
Phase 1(1)
Phase 4(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT07182656Phase 1Recruiting
Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants
Role: lead
NCT05864261Phase 4Completed
Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
Role: lead
All 2 trials loaded